<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang xml:lang>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Your Digest for Wednesday, Mar 20, 2024 09:59 PM</title>
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    span.underline{text-decoration: underline;}
    div.column{display: inline-block; vertical-align: top; width: 50%;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
  </style>
  <style type="text/css">
:root,
::backdrop {

--sans-font: -apple-system, BlinkMacSystemFont, "Avenir Next", Avenir,
"Nimbus Sans L", Roboto, "Noto Sans", "Segoe UI", Arial, Helvetica,
"Helvetica Neue", sans-serif;
--mono-font: Consolas, Menlo, Monaco, "Andale Mono", "Ubuntu Mono", monospace;
--standard-border-radius: 5px;

--bg: #fff;
--accent-bg: #f5f7ff;
--text: #212121;
--text-light: #585858;
--border: #898EA4;
--accent: #0d47a1;
--code: #d81b60;
--preformatted: #444;
--marked: #ffdd33;
--disabled: #efefef;
}

@media (prefers-color-scheme: dark) {
:root,
::backdrop {
color-scheme: dark;
--bg: #212121;
--accent-bg: #2b2b2b;
--text: #dcdcdc;
--text-light: #ababab;
--accent: #ffb300;
--code: #f06292;
--preformatted: #ccc;
--disabled: #111;
}

img,
video {
opacity: 0.8;
}
}

*, *::before, *::after {
box-sizing: border-box;
}

textarea,
select,
input,
progress {
appearance: none;
-webkit-appearance: none;
-moz-appearance: none;
}
html {

font-family: var(--sans-font);
scroll-behavior: smooth;
}

body {
color: var(--text);
background-color: var(--bg);
font-size: 1.15rem;
line-height: 1.5;
display: grid;
grid-template-columns: 1fr min(45rem, 90%) 1fr;
margin: 0;
}
body > * {
grid-column: 2;
}

body > header {
background-color: var(--accent-bg);
border-bottom: 1px solid var(--border);
text-align: center;
padding: 0 0.5rem 2rem 0.5rem;
grid-column: 1 / -1;
}
body > header h1 {
max-width: 1200px;
margin: 1rem auto;
}
body > header p {
max-width: 40rem;
margin: 1rem auto;
}

main {
padding-top: 1.5rem;
}
body > footer {
margin-top: 4rem;
padding: 2rem 1rem 1.5rem 1rem;
color: var(--text-light);
font-size: 0.9rem;
text-align: center;
border-top: 1px solid var(--border);
}

h1 {
font-size: 3rem;
}
h2 {
font-size: 2.6rem;
margin-top: 3rem;
}
h3 {
font-size: 2rem;
margin-top: 3rem;
}
h4 {
font-size: 1.44rem;
}
h5 {
font-size: 1.15rem;
}
h6 {
font-size: 0.96rem;
}

p, h1, h2, h3, h4, h5, h6 {
overflow-wrap: break-word;
}

h1,
h2,
h3 {
line-height: 1.1;
}

@media only screen and (max-width: 720px) {
h1 {
font-size: 2.5rem;
}
h2 {
font-size: 2.1rem;
}
h3 {
font-size: 1.75rem;
}
h4 {
font-size: 1.25rem;
}
}

a,
a:visited {
color: var(--accent);
}
a:hover {
text-decoration: none;
}
button,
.button,
a.button, 
input[type="submit"],
input[type="reset"],
input[type="button"],
label[type="button"] {
border: none;
border-radius: var(--standard-border-radius);
background-color: var(--accent);
font-size: 1rem;
color: var(--bg);
padding: 0.7rem 0.9rem;
margin: 0.5rem 0;
text-decoration: none;
font-family: inherit;
line-height: normal;
}
.button[aria-disabled="true"], input:disabled,
textarea:disabled,
select:disabled,
button[disabled] {
cursor: not-allowed;
background-color: var(--disabled);
color: var(--text-light)
}
input[type="range"] {
padding: 0;
}

abbr[title] {
cursor: help;
text-decoration-line: underline;
text-decoration-style: dotted;
}
button:enabled:hover,
.button:not([aria-disabled="true"]):hover,
input[type="submit"]:enabled:hover,
input[type="reset"]:enabled:hover,
input[type="button"]:enabled:hover,
label[type="button"]:hover {
filter: brightness(1.4);
cursor: pointer;
}
.button:focus-visible,
button:focus-visible:where(:enabled),
input:enabled:focus-visible:where(
[type="submit"],
[type="reset"],
[type="button"]
) {
outline: 2px solid var(--accent);
outline-offset: 1px;
}

header > nav {
font-size: 1rem;
line-height: 2;
padding: 1rem 0 0 0;
}

header > nav ul,
header > nav ol {
align-content: space-around;
align-items: center;
display: flex;
flex-direction: row;
flex-wrap: wrap;
justify-content: center;
list-style-type: none;
margin: 0;
padding: 0;
}

header > nav ul li,
header > nav ol li {
display: inline-block;
}
header > nav a,
header > nav a:visited {
margin: 0 0.5rem 1rem 0.5rem;
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
color: var(--text);
display: inline-block;
padding: 0.1rem 1rem;
text-decoration: none;
}
header > nav a:hover,
header > nav a.current,
header > nav a[aria-current="page"] {
border-color: var(--accent);
color: var(--accent);
cursor: pointer;
}

@media only screen and (max-width: 720px) {
header > nav a {
border: none;
padding: 0;
text-decoration: underline;
line-height: 1;
}
}

aside, details, pre, progress {
background-color: var(--accent-bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
aside {
font-size: 1rem;
width: 30%;
padding: 0 15px;
margin-inline-start: 15px;
float: right;
}
*[dir="rtl"] aside {
float: left;
}

@media only screen and (max-width: 720px) {
aside {
width: 100%;
float: none;
margin-inline-start: 0;
}
}
article, fieldset, dialog {
border: 1px solid var(--border);
padding: 1rem;
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
article h2:first-child,
section h2:first-child {
margin-top: 1rem;
}
section {
border-top: 1px solid var(--border);
border-bottom: 1px solid var(--border);
padding: 2rem 1rem;
margin: 3rem 0;
}

section + section,
section:first-child {
border-top: 0;
padding-top: 0;
}
section:last-child {
border-bottom: 0;
padding-bottom: 0;
}
details {
padding: 0.7rem 1rem;
}
summary {
cursor: pointer;
font-weight: bold;
padding: 0.7rem 1rem;
margin: -0.7rem -1rem;
word-break: break-all;
}
details[open] > summary + * {
margin-top: 0;
}
details[open] > summary {
margin-bottom: 0.5rem;
}
details[open] > :last-child {
margin-bottom: 0;
}

table {
border-collapse: collapse;
margin: 1.5rem 0;
}
td,
th {
border: 1px solid var(--border);
text-align: start;
padding: 0.5rem;
}
th {
background-color: var(--accent-bg);
font-weight: bold;
}
tr:nth-child(even) {

background-color: var(--accent-bg);
}
table caption {
font-weight: bold;
margin-bottom: 0.5rem;
}

textarea,
select,
input {
font-size: inherit;
font-family: inherit;
padding: 0.5rem;
margin-bottom: 0.5rem;
color: var(--text);
background-color: var(--bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
box-shadow: none;
max-width: 100%;
display: inline-block;
}
label {
display: block;
}
textarea:not([cols]) {
width: 100%;
}

select:not([multiple]) {
background-image: linear-gradient(45deg, transparent 49%, var(--text) 51%),
linear-gradient(135deg, var(--text) 51%, transparent 49%);
background-position: calc(100% - 15px), calc(100% - 10px);
background-size: 5px 5px, 5px 5px;
background-repeat: no-repeat;
padding-inline-end: 25px;
}
*[dir="rtl"] select:not([multiple]) {
background-position: 10px, 15px;
}

input[type="checkbox"],
input[type="radio"] {
vertical-align: middle;
position: relative;
width: min-content;
}
input[type="checkbox"] + label,
input[type="radio"] + label {
display: inline-block;
}
input[type="radio"] {
border-radius: 100%;
}
input[type="checkbox"]:checked,
input[type="radio"]:checked {
background-color: var(--accent);
}
input[type="checkbox"]:checked::after {

content: " ";
width: 0.18em;
height: 0.32em;
border-radius: 0;
position: absolute;
top: 0.05em;
left: 0.17em;
background-color: transparent;
border-right: solid var(--bg) 0.08em;
border-bottom: solid var(--bg) 0.08em;
font-size: 1.8em;
transform: rotate(45deg);
}
input[type="radio"]:checked::after {

content: " ";
width: 0.25em;
height: 0.25em;
border-radius: 100%;
position: absolute;
top: 0.125em;
background-color: var(--bg);
left: 0.125em;
font-size: 32px;
}

@media only screen and (max-width: 720px) {
textarea,
select,
input {
width: 100%;
}
}

input[type="color"] {
height: 2.5rem;
padding: 0.2rem;
}

input[type="file"] {
border: 0;
}

hr {
border: none;
height: 1px;
background: var(--border);
margin: 1rem auto;
}
mark {
padding: 2px 5px;
border-radius: var(--standard-border-radius);
background-color: var(--marked);
color: black;
}
img,
video {
max-width: 100%;
height: auto;
border-radius: var(--standard-border-radius);
}
figure {
margin: 0;
display: block;
overflow-x: auto;
}
figcaption {
text-align: center;
font-size: 0.9rem;
color: var(--text-light);
margin-bottom: 1rem;
}
blockquote {
margin-inline-start: 2rem;
margin-inline-end: 0;
margin-block: 2rem;
padding: 0.4rem 0.8rem;
border-inline-start: 0.35rem solid var(--accent);
color: var(--text-light);
font-style: italic;
}
cite {
font-size: 0.9rem;
color: var(--text-light);
font-style: normal;
}
dt {
color: var(--text-light);
}

code,
pre,
pre span,
kbd,
samp {
font-family: var(--mono-font);
color: var(--code);
}
kbd {
color: var(--preformatted);
border: 1px solid var(--preformatted);
border-bottom: 3px solid var(--preformatted);
border-radius: var(--standard-border-radius);
padding: 0.1rem 0.4rem;
}
pre {
padding: 1rem 1.4rem;
max-width: 100%;
overflow: auto;
color: var(--preformatted);
}

pre code {
color: var(--preformatted);
background: none;
margin: 0;
padding: 0;
}



progress {
width: 100%;
}
progress:indeterminate {
background-color: var(--accent-bg);
}
progress::-webkit-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent-bg);
}
progress::-webkit-progress-value {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
}
progress::-moz-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
transition-property: width;
transition-duration: 0.3s;
}
progress:indeterminate::-moz-progress-bar {
background-color: var(--accent-bg);
}
dialog {
max-width: 40rem;
margin: auto;
}
dialog::backdrop {
background-color: var(--bg);
opacity: 0.8;
}
@media only screen and (max-width: 720px) {
dialog {
max-width: 100%;
margin: auto 1em;
}
}

.notice {
background: var(--accent-bg);
border: 2px solid var(--border);
border-radius: 5px;
padding: 1.5rem;
margin: 2rem 0;
}

strong{
color:#d81b60;
}
em {
color:#e0467e; 
}
hr
{
border: 1px;
clear: both;
display: block;
width: 100%;
height: 1px;

background-color:#686868
}
</style>
</head>
<body>
<header id="title-block-header">
<h1 class="title">Your Digest for Wednesday, Mar 20, 2024 09:59 PM</h1>
</header>
<hr />
<ul>
<li>All diuretics</li>
<li>Sulfonylureas</li>
<li>SSRIs and other antidepressants</li>
<li>Carbamazepine,</li>
<li>PPIs</li>
<li>ACE inhibitors, ARBs</li>
<li>Metolazone</li>
<li>Indapamide, setraline, amiloride, carbamazepine, fluoxetine</li>
</ul>
<hr />
<ul>
<li><p>Parasite: Wuchereria bancrofti.</p></li>
<li><p>Vector: Culex quinquefasciatus<br />
- <strong>no filaria visible in the blood.</strong> (also called <strong>OCCULT FILARIASIS</strong>)<br />
- Presents as <em>dry cough with diurnal variation</em><br />
<strong>Complications</strong></p></li>
<li><p>[[2021-SBR-November#Tropical pulmonary eosinophilia (Weingarten syndrome)|Tropical pulmonary eosinophilia]]</p></li>
<li><p><em>Eosinophilia</em> with elevated IgE.</p></li>
<li><p><em>DEC provocation test</em>:</p>
<ul>
<li>Blood was sampled at night.</li>
</ul></li>
<li><p>TPE - <em>diethylcarbamazine for 21 days</em>.</p></li>
</ul>
<hr />
<ul>
<li>Adenomas are commoner in <em>young females</em>.</li>
<li>Adrenal <em>adenoma is seen only in 20-30%</em>.</li>
</ul>
<blockquote>
<p><em>Hypokalemia</em> is more common with adrenal adenomas (vs.bilateral adrenal hyperplasia)<br />
&#39;Muscle weakness&#39; as a symptom is <em>more common with adenomas</em>.<br />
[!INFO] Conn&#39;s syndrome = <em>primary</em> hyper aldosteronism</p>
</blockquote>
<p>#2015MC/Q55<br />
<strong>Elevated ARR</strong> (aldosterone renin ratio) is a screening test:</p>
<ul>
<li>⭐<strong>Confirmatory test:</strong> <em>Inadequate suppression of aldosterone following infusion of 2L of N/S over 4 hours</em>.</li>
</ul>
<p><strong>Management of Conn&#39;s syndrome</strong></p>
<hr />
<pre><code>+ mechanisms for hyponatremia in cortisol deficiency are (1) **impaired renal water handling in the absence of circulating cortisol** and (2) increased plasma concentrations of arginine vasopressin (AVP), despite hypo-osmolality [Source](https://pubmed.ncbi.nlm.nih.gov/32097946/#:~:text=The%20underlying%20mechanisms%20for%20the,)%2C%20despite%20hypo%2Dosmolality.)
</code></pre>
<hr />
<blockquote>
<p>[!INFO] Is an autoimmume, <em>T cell infiltrative</em> disease.</p>
</blockquote>
<ul>
<li><em>Autoimmunity</em> -&gt; TSH-Receptor antibodies (thyrotropin receptor or <em>TRAb</em>) stimulate thyroid gland to make thyroid hormones. -&gt; <em>diffuse, <strong>non tender</strong>, goiter</em>. (MCQ Point: TSH receptor <em>inhibiting antibodies are also formed</em>) <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132101/">Source</a></li>
<li>Histology: Diffuse, <em>hyperplasia and hypertrophy</em>;
<ul>
<li>Opthalmopathy is commoner in <strong>smokers</strong> (UpToDate) #2015MCQ/Q54</li>
</ul></li>
<li><em><strong>Orbitopathy</strong></em> and <em>pretibial myxoedema</em> are not related to thyroxine levels. <em>Orbitopathy does not correlate with disease activity</em>. (can occur after treatment of hyperthyroidism)
<ul>
<li><em>Pretibial myxoedema</em> is caused by deposition of <strong>glycosaminoglycans</strong> (also known as <strong>mucopolysaccharides</strong>) and <strong>T cell infiltration</strong>.</li>
</ul></li>
<li><strong>Acropachy</strong> - a form of clubbing seen in Grave&#39;s disease; <strong>strongly</strong> associated with dermopathy. (visible on X ray)</li>
<li><del>Patients will usually <em>eventually</em> become <em>hypothyroid</em>.</del></li>
</ul>
<blockquote>
<p>A complex series of events causes <em>orbital fibroblasts to produce glycosaminoglycans</em> which accumulate (also increase osmolarity -&gt; orbital oedema) which cause proptosis.</p>
</blockquote>
<h3 id="management-of-graves-disease">Management of Grave&#39;s disease</h3>
<ul>
<li>Management of hyperthyroidism - 12 to 18 months of antithyroid drugs.
<ul>
<li>70% go into permanent remissions.</li>
<li>Can try a second time.</li>
<li>If relapse still occurs, radioiodine or surgery.</li>
<li>Beta blockers for symptomatic relief while the antithyroid drugs work (takes about 3 months)</li>
</ul></li>
<li>Management of eye disease:
<ul>
<li>Steroids : oral or IV (preferred if severe inflammation)</li>
<li>Teprotumumab - monoclonal antibody. (preferred for proptosis and diplopia)</li>
<li>Last line: orbital radiation or orbital decompression surgery.<br />
| General advantages of PTU: Achieves euthyroid state more quickly, Once daily dosing, less likely to cause failure of radioiodine therapy | Usually second choice except for T1, T storm |<br />
| Pruritus, <strong>rash</strong>, arthritis, urticaria, abnormal taste | <strong>Same</strong> |</li>
</ul></li>
</ul>
<hr />
<ul>
<li><strong>Typical history:</strong> <em>Woman</em> of <em>childbearing age</em> who is <em>overweight</em>, presents with episodes of <em>severe throbbing headache</em> with <em>papilloedema</em> (<strong>bilateral</strong> and symmetric) and <em>pulsatile tinnitus</em>.</li>
<li>They can have visual disturbances and <em>diplopia</em> due to <strong>abducens nerve palsy</strong>.</li>
</ul>
<hr />
<ul>
<li><strong>Inheritance</strong> #autosomalDominant</li>
<li>Episodes of angiooedema not responding to <em>anti-histamines</em> or adrenaline, usually after a flu like prodrome.</li>
<li>Caused by C1 esterase deficiency.</li>
<li><strong>No urticaria</strong>.</li>
<li>Deficiency of C1 esterase causes <strong>unchecked activation of C1, C2 and C4</strong>. (i.e classical pathway)
<ul>
<li>Serum <strong>C4 is the most reliable</strong> and widely used screening tool. Low levels of C2 and C4 are seen <strong>even between attacks</strong>.</li>
<li>C1-INH is low only <strong>during an attack</strong></li>
</ul></li>
</ul>
<blockquote>
<p>[!TIP] Mnemonic <del>BARS</del><br />
RBMS</p>
<ul>
<li>Renin angiotensin inhibitors</li>
<li>Beta blockers</li>
<li>MRA</li>
<li>SGLT2<br />
<strong>Aldosterone receptor angatonist (Spironolactone)</strong> - i.e Mineralocorticoid receptor angatonis. (MRA)</li>
</ul>
</blockquote>
<ul>
<li>HFrEF: <del>ARA</del>(MRA) + ACEi or <del>ARA</del>(MRA) + ARB are the preferred combinations</li>
<li>HFpEF: Spironolactone reduces hospitalizations and probably mortality.
<ul>
<li>Main benefit is in EF &lt; 35%.</li>
</ul></li>
<li>Should be started in all patients with stable HFrEF (<strong>particularly those with NYHA II or III symptoms</strong> and who have elevated BNP levels before treatment).<br />
<strong>Diuretics</strong>:
<ul>
<li>Loop diuretics</li>
<li>Metolazone as add on to loop diuretics in refractory cases.</li>
</ul></li>
</ul>
<p><strong>Nitrates and dilators</strong></p>
<ul>
<li>They exert beneficial hemodynamic effects by <strong>decreasing left ventricular filling pressure and systemic vascular resistance while modestly improving cardiac output</strong>.<a href="https://pubmed.ncbi.nlm.nih.gov/7947367/">Source</a></li>
<li>Other vasodilators such as calcium channel blockers are not used to treat LV systolic dysfunction
<ul>
<li>-<strong>SGLT2</strong> inhibitors and <strong>MRAs</strong> reduce the risk of hospitalization.</li>
</ul></li>
</ul>
<ul>
<li>The following agents <strong>are NOT routinely used</strong> because they have not been proven to have benefits in HFpEF!</li>
</ul>
</body>
</html>
